IL1B and non-small cell lung carcinoma: To further explore the potential therapeutic implications, an ongoing phase II clinical trial (NCT04905316) is investigating whether the combination of canakinumab (an anti-IL-1β monoclonal antibody) with chemoradiation and durvalumab proves to be an effective and safe treatment for locally advanced NSCLC.